NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
Clinical Trials
86 trialsNCT03914625 2026-03-18
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05083169 2026-03-18
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04512235 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT04181827 2026-03-16
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05438043 2026-03-16
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06305754 2026-03-13
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06824467 2026-03-13
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05552222 2026-03-12
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05519085 2026-03-11
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT05623020 2026-03-04
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT07327216 2026-03-04
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 3 Recruiting
NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
NCT03150693 2026-03-02
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT03937635 2026-03-02
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-03-02
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT07138209 2026-02-27
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06888817 2026-02-25
BRAINS
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT04162210 2026-02-11
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT06230224 2026-02-06
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT06152575 2026-02-03
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT05020236 2026-02-02
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT06216158 2026-02-02
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Recruiting
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT06932562 2026-01-23
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT07362914 2026-01-23
CHORD
Fudan University
Phase 3 Recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05455320 2026-01-16
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06679101 2026-01-08
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT04655144 2026-01-07
Dex-Fib
University of Miami
Phase 3 Completed
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed